Genitourinary Cancer

Panel 03 - (INTERACTIVE) Hypofractionated Radiation Therapy for Localized Prostate Cancer: ASTRO, ASCO, and AUA Guideline Recommendations and Evidentiary Base

10/21/2018
4:45 PM - 6:15 PM
Location: Lila Cockrell Theatre

Session Type: Panel
1.50 AMA PRA Category 1 Credits™
1.50 CAMPEP Credits
1.50 MDCB Credits

This panel will discuss the recommendations and evidentiary base for Hypofractionated Radiation Therapy for Localized Prostate Cancer: ASTRO, ASCO, and AUA Evidence-Based Guideline. The session will focus on the guideline recommendations developed collaboratively by ASTRO, ASCO, and AUA as well as the underlying evidence. It will address both moderately hypofractionated (240-340 cGy per fraction) and ultrahypofractionated (500 cGy or more per fraction) EBRT regimens compared to conventional fractionation when delivered to the intact prostate. The session will also discuss technical issues, such as normal tissue dose constraints, treatment volumes and use of image-guided and intensity-modulated RT. Finally, the ASTRO guideline development process and the systematic review parameters for this guideline will be briefly presented.

Learning Objectives:

Presentations:

Howard Sandler, MD, MS, FASTRO

Cedars-Sinai Medical Center

Disclosure:
Employment
Cedars-Sinai Medical Center: Chairman, Radiation Oncology: Employee

Compensation
ACR-RTOG: Research Grants

Ownership
Advanced Medical Isotope Corporation: Stock

Leadership
NRG Oncology: Committee Chair

Biography:
Dr. Sandler is Ronald H. Bloom Family Chair in Cancer Therapeutics and Professor and Chairman of Radiation Oncology and a member of the Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles. He received his undergraduate degree, masters in physics and medical degree from the University of Connecticut and completed his training in Radiation Oncology at the University of Pennsylvania. He was recruited to Cedars-Sinai in 2008 from the University of Michigan, where he served as Newman Family Professor of Radiation Oncology. Dr. Sandler’s research interests include prostate and other genitourinary tumors, as well as a broad range of subjects related to radiation oncology. He served as chairman of the Radiation Therapy Oncology Group --now part of NRG Oncology --Genitourinary Cancer Committee from 1997-2018. He has written nearly 300 peer-reviewed publications primarily on prostate cancer and radiation therapy.

Presentation(s):

Send Email for Howard Sandler


Assets

Panel 03 - (INTERACTIVE) Hypofractionated Radiation Therapy for Localized Prostate Cancer: ASTRO, ASCO, and AUA Guideline Recommendations and Evidentiary Base



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Panel 03 - (INTERACTIVE) Hypofractionated Radiation Therapy for Localized Prostate Cancer: ASTRO, ASCO, and AUA Guideline Recommendations and Evidentiary Base